Park Hyo Jung, Kim Dong Wook, Choi Won-Mook, Kim So Yeon
J Korean Soc Radiol. 2025 May;86(3):335-351. doi: 10.3348/jksr.2024.0153. Epub 2025 May 26.
Although US has been widely used for hepatocellular carcinoma (HCC) surveillance, it exhibits limited sensitivity for detecting early-stage HCC. Abbreviated MRI (AMRI) has attracted attention as a superior alternative, offering higher sensitivity for early-stage HCC detection than US and reduced imaging time and cost compared to comprehensive contrast-enhanced MRI. AMRI focuses on essential sequences tailored for HCC detection, with three main strategies: gadoxetate disodium-enhanced hepatobiliary phase AMRI, dynamic contrast-enhanced AMRI, and non-contrast AMRI. In this review, we aim to highlight the technical considerations, performance, and strengths and limitations of each AMRI strategy as well as reporting strategies and recall practices. In addition, to maximize HCC surveillance efficacy using AMRI, a risk-adapted strategy tailored to different patient groups would be necessary, which we will also explore in this review.
尽管超声(US)已广泛用于肝细胞癌(HCC)的监测,但它在检测早期HCC方面的敏感性有限。简化磁共振成像(AMRI)作为一种更优的替代方法受到关注,它对早期HCC检测的敏感性高于超声,且与全面的对比增强磁共振成像相比,成像时间和成本更低。AMRI专注于为HCC检测量身定制的关键序列,有三种主要策略:钆塞酸二钠增强肝胆期AMRI、动态对比增强AMRI和非对比AMRI。在本综述中,我们旨在强调每种AMRI策略的技术考量、性能以及优缺点,以及报告策略和召回实践。此外,为了通过AMRI最大限度地提高HCC监测效能,针对不同患者群体制定风险适应性策略将是必要的,我们也将在本综述中对此进行探讨。